Enlivex Therapeutics (NASDAQ:ENLV) Trading Down 8.8% – Time to Sell?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) shares traded down 8.8% during trading on Friday . The stock traded as low as $6.95 and last traded at $6.75. 24,788 shares traded hands during trading, a decline of 26% from the average daily volume of 33,360 shares. The stock had previously closed at $7.40.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. Finally, HC Wainwright boosted their target price on Enlivex Therapeutics from $195.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $247.50.

Enlivex Therapeutics Price Performance

The company has a market capitalization of $115.52 million, a P/E ratio of -0.83 and a beta of 1.52. The firm’s 50-day moving average is $10.15 and its 200-day moving average is $13.18.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of hedge funds have recently modified their holdings of ENLV. HRT Financial LP increased its stake in Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after buying an additional 135,198 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Enlivex Therapeutics by 99.4% during the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after acquiring an additional 156,336 shares during the last quarter. Jane Street Group LLC lifted its stake in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares in the last quarter. Invesco Ltd. purchased a new position in shares of Enlivex Therapeutics during the fourth quarter valued at about $43,000. Finally, XTX Topco Ltd lifted its position in shares of Enlivex Therapeutics by 44.8% in the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after buying an additional 19,132 shares in the last quarter. 1.02% of the stock is currently owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.